Quantbot Technologies LP Invests $1.03 Million in 10x Genomics, Inc. (NASDAQ:TXG)

Quantbot Technologies LP acquired a new position in 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 71,429 shares of the company’s stock, valued at approximately $1,026,000. Quantbot Technologies LP owned about 0.06% of 10x Genomics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of TXG. Assenagon Asset Management S.A. acquired a new position in 10x Genomics in the 4th quarter valued at approximately $26,308,000. Point72 Asset Management L.P. acquired a new position in shares of 10x Genomics in the third quarter valued at $27,778,000. ARK Investment Management LLC lifted its position in 10x Genomics by 11.1% in the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock worth $171,517,000 after purchasing an additional 1,193,712 shares during the period. SVB Wealth LLC acquired a new stake in 10x Genomics during the fourth quarter worth $7,505,000. Finally, FMR LLC increased its holdings in 10x Genomics by 2.7% in the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company’s stock valued at $301,849,000 after buying an additional 357,470 shares during the period. Institutional investors own 84.68% of the company’s stock.

10x Genomics Trading Down 6.2 %

Shares of NASDAQ TXG opened at $9.75 on Wednesday. 10x Genomics, Inc. has a 1-year low of $9.27 and a 1-year high of $38.49. The company has a 50-day moving average of $12.46 and a two-hundred day moving average of $15.30. The company has a market cap of $1.19 billion, a PE ratio of -6.41 and a beta of 1.93.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, equities research analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Insider Activity

In other 10x Genomics news, Director Alan Mateo acquired 40,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were acquired at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now directly owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This represents a 184.41 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now directly owns 335,324 shares of the company’s stock, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. cut their price target on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday. Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. Finally, Barclays decreased their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.21.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.